See more : Pure Gold Mining Inc. (LRTNF) Income Statement Analysis – Financial Results
Complete financial analysis of Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chengdu Kanghua Biological Products Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Strait Innovation Internet Co., Ltd. (300300.SZ) Income Statement Analysis – Financial Results
- China Aviation Oil (Singapore) Corporation Ltd (G92.SI) Income Statement Analysis – Financial Results
- Troubadour Resources Inc. (TROUF) Income Statement Analysis – Financial Results
- Equatorial Maranhão Distribuidora de Energia S.A. (EQMA3B.SA) Income Statement Analysis – Financial Results
- PT Astra International Tbk (PTAIY) Income Statement Analysis – Financial Results
Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ)
About Chengdu Kanghua Biological Products Co., Ltd.
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.58B | 1.45B | 1.29B | 1.04B | 554.64M | 559.47M | 261.93M | 92.92M | 71.07M |
| Cost of Revenue | 103.78M | 93.13M | 83.75M | 62.84M | 32.35M | 31.09M | 27.62M | 8.63M | 11.10M |
| Gross Profit | 1.47B | 1.35B | 1.21B | 975.79M | 522.29M | 528.38M | 234.31M | 84.29M | 59.97M |
| Gross Profit Ratio | 93.42% | 93.56% | 93.52% | 93.95% | 94.17% | 94.44% | 89.46% | 90.72% | 84.38% |
| Research & Development | 253.03M | 179.94M | 78.88M | 58.25M | 22.79M | 18.92M | 4.27M | 6.36M | 5.01M |
| General & Administrative | 25.30M | 24.91M | 30.95M | 33.27M | 29.23M | 29.18M | 4.08M | 19.53M | 14.72M |
| Selling & Marketing | 495.44M | 428.12M | 412.07M | 371.04M | 217.04M | 249.02M | 110.80M | 29.98M | 12.49M |
| SG&A | 610.87M | 453.03M | 443.02M | 404.32M | 246.27M | 278.19M | 114.88M | 49.51M | 27.21M |
| Other Expenses | 33.11M | 50.19M | 269.15M | -1.12M | -71.22K | -205.19K | -29.81K | 384.68K | 1.43M |
| Operating Expenses | 897.00M | 688.12M | 567.51M | 499.97M | 291.99M | 313.85M | 131.87M | 56.58M | 32.49M |
| Cost & Expenses | 1.00B | 781.26M | 651.26M | 562.81M | 324.34M | 344.94M | 159.49M | 65.21M | 43.59M |
| Interest Income | 12.59M | 14.26M | 21.28M | 12.46M | 668.48K | 298.35K | 416.34K | 433.67K | 484.03K |
| Interest Expense | 4.81M | 3.19M | 72.69K | 230.79K | 532.84K | 441.64K | 5.12M | 10.11M | 11.56M |
| Depreciation & Amortization | 51.46M | 40.95M | 21.82M | 13.98M | 10.00M | 9.34M | 9.72M | 9.97M | 10.19M |
| EBITDA | 630.26M | 728.08M | 937.53M | 496.43M | 233.87M | 199.22M | 105.73M | 26.38M | 34.76M |
| EBITDA Ratio | 39.96% | 53.04% | 73.71% | 48.29% | 43.27% | 40.03% | 42.95% | 41.43% | 55.69% |
| Operating Income | 576.61M | 685.50M | 915.76M | 485.06M | 223.40M | 189.63M | 90.91M | 6.73M | 13.49M |
| Operating Income Ratio | 36.55% | 47.38% | 70.85% | 46.70% | 40.28% | 33.89% | 34.71% | 7.25% | 18.99% |
| Total Other Income/Expenses | -2.62M | -1.71M | -178.65K | -1.12M | -71.22K | -205.19K | -29.81K | 384.68K | 1.43M |
| Income Before Tax | 573.99M | 683.79M | 915.58M | 483.94M | 223.33M | 189.42M | 90.88M | 7.12M | 14.93M |
| Income Before Tax Ratio | 36.39% | 47.26% | 70.84% | 46.59% | 40.27% | 33.86% | 34.69% | 7.66% | 21.01% |
| Income Tax Expense | 64.78M | 85.73M | 86.10M | 75.89M | 36.65M | 35.28M | 16.42M | 460.73K | 3.23M |
| Net Income | 509.22M | 598.07M | 829.48M | 408.05M | 186.69M | 154.14M | 74.46M | 6.66M | 11.70M |
| Net Income Ratio | 32.28% | 41.34% | 64.18% | 39.29% | 33.66% | 27.55% | 28.43% | 7.17% | 16.47% |
| EPS | 3.81 | 4.47 | 6.15 | 3.02 | 1.38 | 1.54 | 0.55 | 0.05 | 0.09 |
| EPS Diluted | 3.81 | 4.46 | 6.14 | 3.02 | 1.38 | 1.54 | 0.55 | 0.05 | 0.09 |
| Weighted Avg Shares Out | 133.75M | 133.94M | 134.97M | 135.00M | 135.00M | 100.24M | 135.00M | 135.00M | 135.00M |
| Weighted Avg Shares Out (Dil) | 133.75M | 133.98M | 135.00M | 135.00M | 135.00M | 100.24M | 135.00M | 135.00M | 135.00M |
Source: https://incomestatements.info
Category: Stock Reports